-
collection "four King Kong", PD-(L)1 both China and the United States, what is the difference between the top 10 popular targets?
Time of Update: 2022-12-30
PD-(L)1 has been the hottest target in recent years, and nearly 20 PD-(L)1 monoclonal antibody drugs have been approved for marketing worldwide since 2014.
PD-(L)1 has been the hottest target in recent years, and nearly 20 PD-(L)1 monoclonal antibody drugs have been approved for marketing worldwide since 2014.
-
Zebutinib is expected to hit the blockbuster for 3 years on the market, PD-1 stands out, and what did BeiGene do right?
Time of Update: 2022-09-14
It is worth noting that in the first half of this year, Baekje's global commercialization pace is the next city, expanding production and construction to the United States, in addition to the already built production bases in Suzhou and Guangzhou, China, at the end of April, the company announced that the commercialization stage of biological agent production and clinical research and development center established in New Jersey officially broke ground.
-
"KOT" dominates the $36 billion global PD-(L)1 market, accounting for more than 90%. Hengrui Xinda Baekje Junshi, rely on what competition?
Time of Update: 2022-09-09
According to the information disclosed in the 2022 semi-annual report of Hengrui Pharmaceutical, at present, carellizumab has been approved for 8 indications in China, and the treatment areas involve lymphoma, hepatocellular carcinoma, esophageal squamous cell carcinoma, nasopharyngeal cancer and non-small cell lung cancer.
-
There are 13 PD-(L)1 models in China, and the competition is fierce. What can the late entrants rely on?
Time of Update: 2022-04-28
HK) announced that its first self-developed innovative biopharmaceutical PD-1 inhibitor H drug-Hanszoid® (generic name: slulimumab injection) Liquid) was officially approved by the State Food and Drug Administration for the indication of adult advanced solid tumors with unresectable or metastatic microsatellite instability-high (MSI-H) who have failed previous standard therapy .
-
"The Lancet-Oncology": What about PD-(L)1 resistance in NSCLC patients?
Time of Update: 2022-02-20
Previous studies have confirmed that the combination of PD(L)-1 inhibitors and CTLA-4 inhibitors shows synergy and has been used for first-line treatment of metastatic non-small cell lung cancer (NSCLC) .
-
What are the highlights of the first domestically produced PD-L1?
Time of Update: 2021-12-03
On November 25, Envolimab, the strategic cooperation between Sidi Medicine, Corning Jerry and Simcere, was officially approved by the National Medical Products Administration, which means that the first domestically produced PD-L1 product will soon be on the market .
-
Prostate Cancer PD: What effect does enzalutamide have on the fatigue of prostate cancer patients?
Time of Update: 2021-10-10
Recently, researchers from Belgium published an article in "Prostate Cancer PD", using four enzalutamide-placebo controlled trials (ARCHES (NCT02677896), PROSPER (NCT02003924), PREVALIL (NCT01212991) and AFFIRM (NCT00974311)) The results reported by patients in the medium, assessing the effect of enzalutamide on patient-reported fatigue .
-
What is the clinical advantage of domestic PD-(L)1 compared with the products of multinational pharmaceutical companies?
Time of Update: 2021-10-01
In addition, on the basis of crossover trials, the absolute PFS and OS benefits and risk ratios of tereprizumab do not look as impressive as Keytruda's Keynote-189 and 407 studies .
-
Nat Med: What is the effect of tumor infiltrating lymphocyte treatment for patients with anti-PD-1 drug-resistant metastatic lung cancer?
Time of Update: 2021-08-26
It can be seen that autologous TIL cell therapy is generally safe and clinically active, and may be used as a new treatment for patients with metastatic lung cancer .
Autologous TIL cell therapy is generally safe and clinically active, and may be used as a new treatment for patients with metastatic lung cancer .
-
Second-line indications for liver cancer: What is the efficacy of domestic PD-1 when drug O is withdrawn and drug K is approved?
Time of Update: 2021-07-30
However, in the confirmatory clinical trial CheckMate-459, according to the pre-specified analysis, O drug and sorafenib first-line treatment of liver cancer, although the ORR data consistent with the previous accelerated approval was achieved, the primary endpoint of OS did not reach the statistics.
-
The market demand cannot hold up to 84 PD-1/L1 products. What will the latecomers survive?
Time of Update: 2021-05-03
Sales are a key factor in testing the commercialization capabilities of pharmaceutical companies, and the market prospects of domestically produced PD-1 monoclonal antibody varieties have been further clarified.
-
See the trick: What should I do if PD-1/PD-L1 immunotherapy drugs are resistant?
Time of Update: 2021-04-27
· Internal reasons for drug resistance: tumor cells are very cunning and will bypass immunotherapy through many mechanisms, such as affecting neoantigen expression, antigen presentation, and affecting immune co-suppressive signals.
-
The market demand cannot hold up to 84 PD-1/L1 products. What will the latecomers survive?
Time of Update: 2021-03-29
Sales are a key factor in testing the commercialization capabilities of pharmaceutical companies, and the market prospects of domestically produced PD-1 monoclonal antibody varieties have been further clarified.
-
See the trick: What should I do if PD-1/PD-L1 immunotherapy drugs are resistant?
Time of Update: 2021-03-27
· Internal reasons for drug resistance: tumor cells are very cunning and will bypass immunotherapy through many mechanisms, such as affecting neoantigen expression, antigen presentation, and affecting immune co-suppressive signals.
-
What are the targets of joint PD-1/PD-L1 therapy that are of concern?
Time of Update: 2021-01-03
2018 Cancer Institute report noted that while the number of clinical trials of PD-1/PD-L1 antibody combination therapy targeted in anti-PD-1/PD-L1 antibody combination therapy (Photo Source: Reference 1)) generally declined, the 2018 Cancer Institute report noted that while the number of clinical trials of PD-1/PD-L1 antibody trials is rising rapidly, the rate of patient recruitment is declining.
